FENC
NASDAQ · Biotechnology
Fennec Pharmaceuticals Inc
$7.84
+0.18 (+2.35%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 74.30M | 77.18M | 58.63M |
| Net Income | -6,101,542 | -7,191,772 | -4,667,510 |
| EPS | — | — | — |
| Profit Margin | -8.2% | -9.3% | -8.0% |
| Rev Growth | -7.2% | -5.1% | +12.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 73.87M | 65.09M | 81.68M |
| Total Equity | 146.21M | 144.26M | 154.72M |
| D/E Ratio | 0.51 | 0.45 | 0.53 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -9,610,170 | -10,191,915 | -7,485,493 |
| Free Cash Flow | -4,689,819 | -4,353,916 | -4,382,896 |